- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04159597
Expanded Access to Upadacitinib
August 2, 2021 updated by: AbbVie
This is an expanded access program (EAP) for eligible participants.
This program is designed to provide access to upadacitinib prior to approval by the local regulatory agency.
Availability will depend on territory eligibility.
A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Study Overview
Status
No longer available
Conditions
Intervention / Treatment
Study Type
Expanded Access
Expanded Access Type
- Individual Patients
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- The participant must not be eligible for upadacitinib clinical trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: ABBVIE INC., AbbVie
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
November 7, 2019
First Submitted That Met QC Criteria
November 7, 2019
First Posted (Actual)
November 12, 2019
Study Record Updates
Last Update Posted (Actual)
August 9, 2021
Last Update Submitted That Met QC Criteria
August 2, 2021
Last Verified
August 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- C20-082
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atopic Dermatitis (AD)
-
Catalysis SLCompletedAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related Conditions | Atopic Dermatitis \(AD\)Serbia
-
AbbVieActive, not recruiting
-
National Institute of Allergy and Infectious Diseases...Sanofi; Regeneron Pharmaceuticals; Rho Federal Systems Division, Inc.; Atopic Dermatitis...TerminatedAtopic Dermatitis (AD)United States
-
AbbVieWithdrawn
-
Regeneron PharmaceuticalsSanofiCompletedStudy to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD)Atopic Dermatitis (AD)United States, Canada
-
Otsuka Beijing Research InstituteRecruiting
-
Otsuka Pharmaceutical Co., Ltd.Completed
-
Otsuka Beijing Research InstituteRecruitingAtopic Dermatitis (AD)China
-
Johnson & Johnson Consumer Inc. (J&JCI)CompletedAtopic Dermatitis (AD)United States
-
National Institute of Allergy and Infectious Diseases...Atopic Dermatitis Research NetworkCompletedAtopic Dermatitis (AD) | Non-atopic Healthy ControlsUnited States
Clinical Trials on Upadacitinib
-
AbbVieRecruiting
-
AbbVieCompletedCrohn's DiseaseUnited States, Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy and more
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityRecruiting
-
University Hospital, MontpellierRecruitingRheumatoid ArthritisFrance
-
AbbVieActive, not recruitingUlcerative Colitis (UC)United States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Canada, Chile, China, Colombia, Croatia, Czechia, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Japan, Korea, Republic... and more
-
AbbVieNot yet recruiting
-
AbbVieActive, not recruitingAtopic DermatitisUnited States, Argentina, Australia, Bosnia and Herzegovina, Bulgaria, Canada, China, Colombia, Croatia, Denmark, Estonia, Finland, France, Germany, Italy, Japan, Malaysia, New Zealand, Puerto Rico, Romania, Russian Federation, Sw... and more
-
AbbVieActive, not recruitingAtopic DermatitisUnited States, Australia, Austria, Belgium, Bulgaria, Canada, Croatia, Czechia, Denmark, France, Germany, Greece, Hungary, Ireland, Italy, Korea, Republic of, Netherlands, New Zealand, Portugal, Singapore, Spain, Taiwan, United Kingdom
-
AbbVieCompletedCrohn's DiseaseUnited States, Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy and more